AU2017260232B2 - Anti-Kv1.3 antibodies, and methods of production and use thereof - Google Patents

Anti-Kv1.3 antibodies, and methods of production and use thereof Download PDF

Info

Publication number
AU2017260232B2
AU2017260232B2 AU2017260232A AU2017260232A AU2017260232B2 AU 2017260232 B2 AU2017260232 B2 AU 2017260232B2 AU 2017260232 A AU2017260232 A AU 2017260232A AU 2017260232 A AU2017260232 A AU 2017260232A AU 2017260232 B2 AU2017260232 B2 AU 2017260232B2
Authority
AU
Australia
Prior art keywords
gly
ser
ala
thr
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017260232A
Other languages
English (en)
Other versions
AU2017260232A1 (en
Inventor
Alka Agrawal
Janna BEDNENKO
Yelena BISHARYAN
Joanna CARDARELLI
Theodore G. Clark
Ellen J. Collarini
Paul Colussi
Hans De Haard
William D. Harriman
R. Douglas Kahn
Lore MARIEN
Ashot Papoyan
Bas Van der Woning
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abcellera Boston Inc
Original Assignee
Abcellera Boston Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abcellera Boston Inc filed Critical Abcellera Boston Inc
Publication of AU2017260232A1 publication Critical patent/AU2017260232A1/en
Application granted granted Critical
Publication of AU2017260232B2 publication Critical patent/AU2017260232B2/en
Assigned to ABCELLERA BOSTON, INC. reassignment ABCELLERA BOSTON, INC. Amend patent request/document other than specification (104) Assignors: TetraGenetics Inc.
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2017260232A 2016-05-02 2017-05-02 Anti-Kv1.3 antibodies, and methods of production and use thereof Ceased AU2017260232B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662330420P 2016-05-02 2016-05-02
US62/330,420 2016-05-02
US201662416447P 2016-11-02 2016-11-02
US62/416,447 2016-11-02
PCT/US2017/030612 WO2017192567A1 (en) 2016-05-02 2017-05-02 ANTI-Kv1.3 ANTIBODIES, AND METHODS OF PRODUCTION AND USE THEREOF

Publications (2)

Publication Number Publication Date
AU2017260232A1 AU2017260232A1 (en) 2018-11-29
AU2017260232B2 true AU2017260232B2 (en) 2024-07-18

Family

ID=60203481

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017260232A Ceased AU2017260232B2 (en) 2016-05-02 2017-05-02 Anti-Kv1.3 antibodies, and methods of production and use thereof

Country Status (8)

Country Link
US (1) US11597763B2 (https=)
EP (1) EP3452084A4 (https=)
JP (2) JP7082065B2 (https=)
CN (1) CN109862907A (https=)
AU (1) AU2017260232B2 (https=)
CA (1) CA3022961A1 (https=)
IL (1) IL262747A (https=)
WO (1) WO2017192567A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113559075A (zh) 2014-11-17 2021-10-29 康泰科思特生物制药公司 奥那司酮延长释放组合物和方法
WO2018102369A1 (en) 2016-11-30 2018-06-07 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection
EP3793614A4 (en) 2018-04-30 2022-04-20 Integral Molecular, Inc. GLUCOSE TRANSPORTER-4 ANTIBODIES, PROCESSES FOR THEIR PRODUCTION AND THEIR USES
EP3924389A4 (en) 2019-02-15 2023-06-14 Integral Molecular, Inc. CLAUDIN-6 ANTIBODIES AND THEIR USES
CN113661175A (zh) 2019-02-15 2021-11-16 整体分子公司 包含共同轻链的抗体及其用途
CA3176090A1 (en) * 2020-03-30 2021-10-07 Crystal Bioscience Inc. Anti-gipr antibody and methods of use thereof
EP4626933A1 (en) 2022-11-30 2025-10-08 Integral Molecular, Inc. Antibodies directed to claudin 6, including bispecific formats thereof
CN120865419A (zh) * 2025-08-02 2025-10-31 广东工业大学 一种用于检测肝癌标志物gpc3的禽源单链抗体、试剂盒、检测方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861405B2 (en) * 2001-06-12 2005-03-01 Yale University Compositions and methods relating to glucose metabolism, weight control, and food intake
US7319142B1 (en) * 2004-08-31 2008-01-15 Monsanto Technology Llc Nucleotide and amino acid sequences from Xenorhabdus and uses thereof
AU2006324847A1 (en) 2005-12-15 2007-06-21 Genegrafts Ltd. Polynucleotides and polypeptide of Human KV1.3, compositions comprising same and methods of using same
WO2007139771A1 (en) 2006-05-22 2007-12-06 The Johns Hopkins University Kv channels in neurodegeneration and neuroprotection
WO2010126590A1 (en) 2009-04-27 2010-11-04 Cold Spring Harbor Laboratory Ptp1b inhibitors
EP2287202A1 (en) 2009-08-07 2011-02-23 Dublin City University Anti-sialic acid antibody molecules
JP5765814B6 (ja) 2009-10-21 2018-06-27 国立大学法人広島大学 インテグリンα８β１特異的モノクローナル抗体
CN102180950B (zh) 2011-02-24 2013-06-05 华中科技大学同济医学院附属协和医院 一种人源性电压门控钾通道1.3免疫原性肽段及其用途
WO2014016737A1 (en) 2012-07-24 2014-01-30 Pfizer Inc. Novel chicken monoclonal antibodies against human phosphorylated tau and uses thereof
RS57422B1 (sr) 2013-01-25 2018-09-28 Janssen Biotech Inc Antagonisti kv1.3 i postupci za upotrebu
CN103713129B (zh) 2013-12-18 2016-02-10 中国医学科学院北京协和医院 分子标记物在甲状旁腺肿瘤诊断中的用途
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.

Also Published As

Publication number Publication date
WO2017192567A1 (en) 2017-11-09
CN109862907A (zh) 2019-06-07
JP7082065B2 (ja) 2022-06-07
EP3452084A1 (en) 2019-03-13
IL262747A (en) 2018-12-31
EP3452084A4 (en) 2020-01-01
AU2017260232A1 (en) 2018-11-29
US11597763B2 (en) 2023-03-07
CA3022961A1 (en) 2017-11-09
JP2019521651A (ja) 2019-08-08
JP2022002541A (ja) 2022-01-11
US20190144538A1 (en) 2019-05-16

Similar Documents

Publication Publication Date Title
AU2017260232B2 (en) Anti-Kv1.3 antibodies, and methods of production and use thereof
AU2019394241B2 (en) CD3 antibody and pharmaceutical use thereof
US9624291B2 (en) Bi- and monospecific, asymmetric antibodies and methods of generating the same
JP2021054859A (ja) Ｃｄ４７に結合する抗体医薬
TW201632559A (zh) 結合ｃｄ１３７之抗體治療劑
US9567404B2 (en) Anti-vasa antibodies, and methods of production and use thereof
CN112442122B (zh) 阻断型pd-1纳米抗体及其编码序列和用途
WO2022267936A1 (zh) 特异性结合糖基化ceacam5的抗体
JP7837331B2 (ja) Ｃｌｄｎ６及びｃｄ３に選択的に結合するポリペプチド構築物
US12037409B2 (en) Antibody specifically bound to glycosylated CEACAM5
CN111788229A (zh) Csf1r结合剂
KR20230104229A (ko) Cd3에 결합하는 폴리펩티드 구축물
WO2022100694A1 (zh) 抗体及其制备方法
RU2804490C2 (ru) Новые композиции антител для иммунотерапии рака
CN120152991A (zh) 靶向人源ror1的单域抗体
HK40118288A (zh) 包含结合γ-δ T细胞受体的抗体的组合物
CN118667026A (zh) 抗muc17*cd3*cd28三特异性抗体
OA18333A (en) Anti-Vasa antibodies, and methods of production and use thereof
IL228442A (en) Specific asymmetric antibodies against me and methods for their preparation

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ COLUSSI, PAUL; BEDNENKO, JANNA; BISHARYAN, YELENA; PAPOYAN, ASHOT; CARDARELLI, JOANNA; CLARK, THEODORE G.; KAHN, R. DOUGLAS; MARIEN, LORE; VAN DER WONING, BAS; DE HAARD, HANS; HARRIMAN, WILLIAM D.; COLLARINI, ELLEN J. AND AGRAWAL, ALKA

HB Alteration of name in register

Owner name: ABCELLERA BOSTON, INC.

Free format text: FORMER NAME(S): TETRAGENETICS INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired